The Supreme Court is slated to hear a case concerning the federal law known as the Emergency Medical Treatment and Labor Act. The justices consider one of the most pressing questions to emerge since they eliminated the federal constitutional right to an abortion two years ago: Under what circumstances can women with serious pregnancy complications obtain abortions in states where the procedure is banned? (The Wall Street Journal)
A group of venture capitalists and scientists launched a startup called Xaira Therapeutics, which will use AI to transform drug R&D. Marc Tessier-Lavigne, former chief scientific officer of Genentech and president of Stanford University, will head the company as CEO. (Endpoints News)
Learn about how Haleon’s Flonase forged a Bridgerton connection for its ‘Polin’ ad campaign. Flonase is leaning into opportunities to advertise its product in front of Bridgerton’s sizable audience by making the brand a part of the show as authentically as possible. (MM+M)
Nine months after the launch of Eisai and Biogen’s Alzheimer’s drug Leqembi, the drug has been hampered by slow adoption due to concerns among some healthcare providers that Alzheimer’s therapies are futile. Seven doctors told Reuters they’re held back by concerns over Leqembi’s efficacy, cost and risks. (Reuters)
Buyout firm CVC has reportedly explored options for its €11 billion controlling stake in Italian drugmaker Recordati SpA. CVC is working with advisers and is in the early stages of studying alternatives including a potential sale or a combination with another business. (Bloomberg)
Click here to see yesterday’s Five things for pharma marketers to know.
